To the Editor: Non-invasive prenatal testing (NIPT) for trisomy 21 and other chromosomal abnormalities using cell-free fetal DNA became available in Australia on a user-pays basis in 2012.1,2 Since then, the price of this highly accurate screening test has fallen as multiple international providers entered the market, including, earlier this year, the first Australian provider.1,3 The growth in the industry and anecdotal evidence both suggest that demand for the test is increasing rapidly.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1. Hui L, Teoh M, da Silva Costa F, et al. Clinical implementation of cell‐free DNA‐based aneuploidy screening: perspectives from a national audit. Ultrasound Obstet Gynecol 2015; 45: 10-15.
- 2. O'Leary P, Maxwell S, Murch A, Hendrie D. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. Aust N Z J Obstet Gynaecol 2013; 53: 425-433.
- 3. Victorian Clinical Genetics Services. Percept: cell-free DNA prenatal test. 2015. http://www.vcgs.org.au/perceptNIPT/ (accessed May 2015).
- 4. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. DNA-based noninvasive prenatal testing for fetal aneuploidy. (College communiqués, 2014). https://www.ranzcog.edu.au/womens-health/college-communiques/1357-dna-based-noninvasive-prenatal-testing-for-fetal-aneuploidy.html (accessed Jan 2015).
- 5. Hyett J. Non-invasive prenatal testing for Down syndrome. Aust Prescr 2014; 37: 51-55.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.